FDA approves abid for Aerie's second new drug, Rocklatan, to go public

recently, Aerie Pharmaceuticals(http:// announcedthat it had approved the listing of its secondnew drug(http://rocklatantheof the Http://About RocklatanDaily Eye Drop Sfluid Rocklatan is a fixed-dose combination of Aerie's first approved eye droph Rhopressa (0.02% netarsudil ophthalmic solution) and 0.005% prostaglandin analogue (PGA) latanoprost to reduce eye pressure (IOP) in open-angle glaucoma or high-eye pressure patientsRocklatan's main component, netarsudil, is a "first-in-class" Rho kinase (ROCK) inhibitor that targets the drainage system in the eye, the trabecular meshBy inhibiting rock's activity, netarsudil can improve the permeability of the small beam network, which is conducive to the discharge of water, thereby reducing the venous pressure of the sclorainIn addition, netarsudil may reduce eye pressure by reducing the production of eye fluidAnother active ingredient in Rocklatan, latanoprost, is a first-line treatment for glaucoma that further increases the discharge of fluid in the eye through an auxiliary mechanism called the "vine membrane sorcea pathway"Rocklatan is the first and only fixed-dose combination therapy consisting of ROCK inhibitors and PGAThe approval of Rocklatan's listing application is based on the results of two Phase 3 trials, Mercury 1 and Mercury 2in two trial (http:// , the Rocklatan group not only reached a 90-day end in efficacy, but also significantly better than patients who used netarsudil or latanoprost alone at each point in time; in addition, , the Rocklatan group achieved iOP 16 mmHg and 14 mmHg patient ratios, which were close to 2 times and 3 times, respectively, in the latanoprost group Rocklatan also demonstrates good security